FDA clears AI-powered glucose monitoring app. The clearance marks a first for an over-the-counter tool in this category.

Tech vendor Reveleer and policy analytics firm Mathematica released their 2025 State of Technology in Value-Based Care report, the findings of which show that AI adoption in healthcare is widespread—but integration is spotty. 

The 22-year-old patient was undergoing a computed tomography exam with contrast due to her history of kidney stones.

The organization is under fire after the patient’s wife charged that it could have prevented her husband’s untimely death. 

Most organizations trying out generative AI—a full 95%—are failing to receive a measurable return on the pilot investment. 

If three sticking points aren’t unstuck soon, older Americans won’t benefit much by the 1,000+ medical devices that, as of 2025, are both equipped with AI and cleared by the FDA. 

The insurance giant is charging the new board committee with monitoring company policies related to prior authorizations, claims adjudication and AI. The group is scheduled to meet four times a year.

Two lots of IV solution bags from the company were found to contain particulate matter that could cause blockages in blood vessels, killing a patient. To date, no serious adverse events have been reported.